Yamaguchi, Kazuya
Yoshida, Kazuhiro
Tanahashi, Toshiyuki
Takahashi, Takao
Matsuhashi, Nobuhisa
Tanaka, Yoshihiro
Tanabe, Kazuaki
Ohdan, Hideki
Funding for this research was provided by:
Japan Society for the Promotion of Science
Article History
Received: 30 January 2017
Accepted: 5 June 2017
First Online: 14 June 2017
Compliance with ethical standards
:
: K. Yoshida has received grants, personal fees and nonfinancial support from Chugai Pharmaceutical Co., Ltd., during the conduct of the study; grants and personal fees from Taiho Pharmaceutical Co., Ltd.; grants and personal fees from Pfizer Inc.; grants and personal fees from Yakult Honsha Co., Ltd.; grants from Bristol-Myers Squibb; grants from Kyowa Hakko Kirin Co., Ltd., outside the submitted work; honoraria from Taiho Pharmaceutical Co., Ltd.; Pfizer Inc.; Chugai Pharmaceutical Co., Ltd.; Kyowa Hakko Kirin Co., Ltd.; Yakult Honsha Co., Ltd.; and had a consultant or advisory relationship to Taiho Pharmaceutical Co., Ltd., and La Roche, Ltd. All remaining authors declared that they have no conflict of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and in compliance with the Helsinki Declaration of 1964 and later versions. Both hospitals disclose information to the patients. Participating patients were excluded only when they specified that they were unwilling to participate.